Abstract
Current treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) are noncurative, and median survival upon development of mCRPC is approximately 3 years. The novel hormonal agent enzalutamide has an established role in the mCRPC treatment paradigm, and emerging evidence suggests potential synergism with enzalutamide and the PD-1 inhibitor pembrolizumab in men with mCRPC. Here, we describe the design and rationale for the multicenter, randomized, double-blind, Phase III KEYNOTE-641 study, which will be conducted to compare the efficacy and safety of pembrolizumab plus enzalutamide with that of enzalutamide plus placebo in mCRPC. Clinical trial registration: NCT03834493 (ClinicalTrials.gov.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3017-3026 |
| Number of pages | 10 |
| Journal | Future Oncology |
| Volume | 17 |
| Issue number | 23 |
| DOIs | |
| State | Published - Aug 2021 |
Keywords
- PD-1
- PD-L1
- castration resistant
- enzalutamide
- mCRPC
- pembrolizumab
- prostate cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research